Animal Healthcare Company Shares Jump 5%; PAT Increases 974% In Q4FY26

Hester Biosciences Limited reported a sharp recovery in profitability for Q4FY26 and the full financial year FY26, driven by strong performance in its Poultry Healthcare Division, improved product mix, and continued cost optimisation. The company announced its results on May 15, 2026.

Following the earnings announcement, Hester Biosciences shares were trading at Rs 1,824 on the NSE, up 4.82 percent for the day. The stock opened at Rs 1,745.50 and touched an Intraday high of Rs 1,990, while the day’s low stood at Rs 1,732.90.

Hester Biosciences Q4FY26 Results
Hester Biosciences Limited reported consolidated revenue from operations of Rs 100.11 crore in Q4FY26 as against Rs 81.93 crore reported in Q4FY25, registering a growth of around 22 per cent YoY.

EBITDA for the quarter came in at Rs 36.10 crore in Q4FY26 compared to Rs 13.54 crore reported in Q4FY25, reflecting a growth of around 167 per cent YoY. EBITDA margin expanded sharply to 36 per cent in Q4FY26 from 17 per cent in Q4FY25.

Gross profit margin improved to 81 per cent in Q4FY26 from 75 per cent in Q4FY25, a gain of 6 percentage points YoY.

Profit after tax stood at Rs 16.55 crore in Q4FY26 as against Rs 1.54 crore reported in Q4FY25, reflecting a growth of around 974 per cent YoY. PAT margin expanded to 17 per cent in Q4FY26 from 2 per cent in Q4FY25.

Hester Biosciences FY26 Performance
For the financial year ended March 31, 2026, Hester Biosciences reported consolidated revenue from operations of Rs 332.60 crore as against Rs 311.10 crore reported in FY25, registering a growth of around 7 per cent annually.

EBITDA for FY26 stood at Rs 105.65 crore compared to Rs 69.08 crore in FY25, reflecting a growth of around 53 per cent on an annual basis. EBITDA margin expanded to 32 per cent in FY26 from 22 per cent in FY25, an improvement of 10 percentage points.

Gross profit margin improved to 75 per cent in FY26 from 72 per cent in FY25. Consolidated profit after tax came in at Rs 57.48 crore in FY26 compared to Rs 28.83 crore reported in FY25, registering a growth of around 99 per cent annually. PAT margin stood at 17 per cent in FY26 against 9 per cent in FY25.

Dividend Declaration
The board has recommended a dividend of Rs 11 per equity share, representing 110 per cent on face value, for FY26, subject to approval of members at the ensuing Annual General Meeting.

Standalone Divisional Performance
On a standalone basis, the Poultry Healthcare Division recorded strong growth, reporting revenue of Rs 65.02 crore in Q4FY26 compared to Rs 46.09 crore in Q4FY25, a growth of 41 per cent YoY. For the full year FY26, the division reported revenue of Rs 206.08 crore against Rs 166.44 crore in FY25, a growth of 24 per cent annually.

The Animal Healthcare Division reported revenue of Rs 28.64 crore in Q4FY26 compared to Rs 30.54 crore in Q4FY25, a decline of 6 per cent YoY, continuing to be impacted by delays in government immunisation programmes and uneven demand across certain commercial markets. For FY26, the division reported revenue of Rs 81.83 crore against Rs 119.88 crore in FY25, a decline of 32 per cent on an annual basis.

Total standalone revenue from operations stood at Rs 93.71 crore in Q4FY26 compared to Rs 76.67 crore in Q4FY25, a growth of 22 per cent YoY. For FY26, standalone revenue from operations came in at Rs 292.14 crore against Rs 286.47 crore in FY25, a growth of 2 per cent annually.

Key Highlights
During the quarter, the company capitalised its BSL 3 facility as part of its ongoing capacity expansion and infrastructure strengthening initiatives. The company also received marketing and manufacturing licences for its H9N2 Avian Influenza vaccine during the quarter, further strengthening its poultry vaccine portfolio.

The company remains focused on strengthening its biologicals portfolio across poultry and animal healthcare, improving market penetration in domestic and export markets, and reducing dependence on institutional business through portfolio diversification. It also continues to strengthen its presence across Africa and other export markets through registrations, market development initiatives, and strategic partnerships.

About the company
Hester Biosciences Ltd is one of the leading animal health care companies & the second largest poultry vaccine manufacturer in India. Founded by Mr. Rajiv Gandhi in 1987, it now has a presence in over 30 countries & has a key market in India, Nepal & Tanzania. It has partnered with Bill & Melinda Gates Foundation, GALVmed, Golchha Organisation, Novapharma, etc. While operating across four broad verticals of Poultry Vaccines, Poultry Health Products, Animal Vaccines and Animal Health Products, the company provides services like seroprofiling kits and diagnostic labs for poultry flocks, and mastitis control programs for cattle.

Share your views in the comments below.

Disclaimer: This article is for informational purposes only and not investment advice.